NOVEN PHARMACEUTICALS INC Form 8-K August 04, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 4, 2005

59-2767632

Noven Pharmaceuticals, Inc

(Exact name of registrant as specified in its charter)

0 - 17254

Delaware	0-17254	59-2767632
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
11960 S.W. 144th Street, Miami, Florida		33186
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area code:		305-253-5099
	Not Applicable	
Former na	me or former address, if changed since l	ast report
Check the appropriate box below if the Form 8-K filing the following provisions:	ing is intended to simultaneously satisfy	the filing obligation of the registrant under any of
Written communications pursuant to Rule 425 un Soliciting material pursuant to Rule 14a-12 unde Pre-commencement communications pursuant to Pre-commencement communications pursuant to	or the Exchange Act (17 CFR 240.14a-12 ORule 14d-2(b) under the Exchange Act) (17 CFR 240.14d-2(b))

Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2005, Noven issued a press release announcing its financial results for the three and six months ended June 30, 2005. This press release, a copy of which is attached hereto as Exhibit 99.1, is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or incorporated by reference into a filing under the Securities Act of 1933 or the Exchange Act.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Noven Pharmaceuticals, Inc

August 4, 2005 By: Diane M. Barrett

Name: Diane M. Barrett

Title: Vice President and Chief Financial Officer

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated August 4, 2005, announcing Noven Pharmaceuticals, Inc.'s financial results for the quarter ended June 30, 2005.